Malaria is caused by Plasmodium parasites and is a major public health issue in many countries, particularly in Africa. It is well established in mice that tissue-resident memory (Trm) CD8+ cells are crucial for protection against liver stage malaria. However, there is no simple vaccine formulation that can effectively generate these cells. Here, we report the development of a synthetic glycolipid-peptide vaccine that is highly effective at inducing liver Trm cells. This vaccine was dependent on priming by XCR1+ type 1 conventional dendritic cells (cDC1s). After initial T cell activation, we showed that antigen and inflammation provided by the conjugate vaccine can further influence the seeding and longevity of liver Trm cells. Our longitudinal analysis revealed that a single vaccination induced large numbers of endogenous malaria-specific Trm cells that persisted for more than 300 days in the liver and conferred substantial protection against sporozoite challenge. The vaccine response can be improved by homologous prime-boost immunization, ideally with a 60-day delay between injections. Lastly, vaccination against Kb90, an MHC-I restricted epitope identified from the peptide library screening, can induce liver Trm generation and confer high levels of sterile protection against malaria, demonstrating the identification of a novel protective malaria epitope. Overall, our results highlight the effectiveness of conjugate vaccines at generating liver Trm-mediated immunity against malaria.